JPWO2020139830A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020139830A5 JPWO2020139830A5 JP2021537818A JP2021537818A JPWO2020139830A5 JP WO2020139830 A5 JPWO2020139830 A5 JP WO2020139830A5 JP 2021537818 A JP2021537818 A JP 2021537818A JP 2021537818 A JP2021537818 A JP 2021537818A JP WO2020139830 A5 JPWO2020139830 A5 JP WO2020139830A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- alox15
- acid molecule
- seq
- nucleotide sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000007523 nucleic acids Chemical class 0.000 claims 73
- 108020004707 nucleic acids Proteins 0.000 claims 64
- 102100010730 ALOX15 Human genes 0.000 claims 56
- 101710022933 ALOX15 Proteins 0.000 claims 56
- 229920001850 Nucleic acid sequence Polymers 0.000 claims 56
- RWQNBRDOKXIBIV-UHFFFAOYSA-N Thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 claims 56
- 230000000875 corresponding Effects 0.000 claims 48
- 230000000295 complement Effects 0.000 claims 32
- 229940113082 Thymine Drugs 0.000 claims 28
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 claims 28
- 239000000523 sample Substances 0.000 claims 28
- 230000001809 detectable Effects 0.000 claims 21
- 230000035772 mutation Effects 0.000 claims 19
- 108020004999 Messenger RNA Proteins 0.000 claims 16
- 238000004166 bioassay Methods 0.000 claims 16
- 239000012472 biological sample Substances 0.000 claims 16
- 229920002106 messenger RNA Polymers 0.000 claims 16
- 229920001184 polypeptide Polymers 0.000 claims 15
- 229920002676 Complementary DNA Polymers 0.000 claims 14
- 229940035893 Uracil Drugs 0.000 claims 14
- 239000002299 complementary DNA Substances 0.000 claims 14
- 239000003112 inhibitor Substances 0.000 claims 9
- 230000002401 inhibitory effect Effects 0.000 claims 9
- 229920002391 Guide RNA Polymers 0.000 claims 7
- 108020005004 Guide RNA Proteins 0.000 claims 7
- 206010038683 Respiratory disease Diseases 0.000 claims 7
- 238000002372 labelling Methods 0.000 claims 6
- 239000004055 small Interfering RNA Substances 0.000 claims 4
- 102200035832 ALOX15 T560M Human genes 0.000 claims 3
- 239000002773 nucleotide Substances 0.000 claims 3
- 125000003729 nucleotide group Chemical group 0.000 claims 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims 2
- 108020004459 Small Interfering RNA Proteins 0.000 claims 2
- 229920001891 Small hairpin RNA Polymers 0.000 claims 2
- 229920001985 Small interfering RNA Polymers 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 238000000338 in vitro Methods 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 102200027750 ABL2 Y139C Human genes 0.000 claims 1
- 102220387559 ALOX15 G422R Human genes 0.000 claims 1
- 206010006334 Breathing abnormality Diseases 0.000 claims 1
- 229920000033 CRISPR Polymers 0.000 claims 1
- 108010082319 CRISPR-Associated Protein 9 Proteins 0.000 claims 1
- 102200114822 F13A1 P565L Human genes 0.000 claims 1
- 102200002559 HNRNPA1 G283R Human genes 0.000 claims 1
- 102200020440 SPAST V474A Human genes 0.000 claims 1
- 230000000692 anti-sense Effects 0.000 claims 1
- 238000003018 immunoassay Methods 0.000 claims 1
Claims (50)
前記対象から得られた生体試料にてヒトALOX15ポリペプチドをコードするALOX15で予測される機能喪失型変異体核酸分子の存在または非存在を決定すること、または決定したことを含み;
前記ヒト対象がALOX15基準である場合、前記ヒト対象は呼吸器障害を発症する高いリスクを有し;且つ
前記ヒト対象がALOX15で予測される機能喪失型変異体についてヘテロ接合である、またはALOX15で予測される機能喪失型変異体についてホモ接合である場合、前記ヒト対象は呼吸器障害を発症する低いリスクを有する、前記方法。 A method of identifying a human subject at high risk for developing a respiratory disorder, said method comprising:
determining, or having determined, the presence or absence of an ALOX15-predicted loss-of-function mutant nucleic acid molecule encoding a human ALOX15 polypeptide in a biological sample obtained from said subject;
if said human subject is ALOX15 criteria, said human subject has an increased risk of developing a respiratory disorder; and said human subject is heterozygous for a predicted loss-of-function variant in ALOX15, or The method, wherein the human subject has a reduced risk of developing a respiratory disorder when homozygous for the predicted loss-of-function variant in .
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862785899P | 2018-12-28 | 2018-12-28 | |
US62/785,899 | 2018-12-28 | ||
PCT/US2019/068328 WO2020139830A2 (en) | 2018-12-28 | 2019-12-23 | Treatment of respiratory disorders with arachidonate15-lipoxygenase (alox15) inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2022515838A JP2022515838A (en) | 2022-02-22 |
JPWO2020139830A5 true JPWO2020139830A5 (en) | 2022-12-13 |
Family
ID=69326713
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021537818A Pending JP2022515838A (en) | 2018-12-28 | 2019-12-23 | Treatment of respiratory disorders with arachidonic acid 15-lipoxygenase (ALOX15) inhibitors |
Country Status (11)
Country | Link |
---|---|
US (1) | US20200254070A1 (en) |
EP (1) | EP3902567A2 (en) |
JP (1) | JP2022515838A (en) |
KR (1) | KR20210110623A (en) |
CN (1) | CN113423435A (en) |
AU (1) | AU2019417718A1 (en) |
CA (1) | CA3124670A1 (en) |
IL (1) | IL284046A (en) |
MX (1) | MX2021007938A (en) |
SG (1) | SG11202106517WA (en) |
WO (1) | WO2020139830A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3911632A1 (en) | 2019-01-15 | 2021-11-24 | Empirico Inc. | Prodrugs of alox-15 inhibitors and methods of using the same |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5932425A (en) | 1997-02-18 | 1999-08-03 | Signal Pharmaceuticals, Inc. | Compositions and methods for modulating cellular NF-κB activation |
FR2762841B1 (en) | 1997-04-30 | 1999-07-02 | Jouveinal Inst Rech | DIAZEPINO-INDOLONES INHIBITING PHOSPHODIESTERASES IV |
KR20000068711A (en) | 1997-08-06 | 2000-11-25 | 도리이 신이치로 | 1-Aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor |
IT1296984B1 (en) | 1997-12-19 | 1999-08-03 | Zambon Spa | PHTHALAZINE DERIVATIVES INHIBITORS OF PHOSPHODIESTERASE 4 |
UA59443C2 (en) | 1998-04-28 | 2003-09-15 | Арцнайміттельверк Дрезден Гмбх | Hydroxyindole, a method for producing THEREOF, medicinal form based THEREON, and a method for producing the same |
PT1086096E (en) | 1998-06-10 | 2003-12-31 | Altana Pharma Ag | BENZAMIDES WITH ETRA-HYDROFURANILOXI SUBSTITUTS AS PHOSPHODIESTERASE 4 INHIBITORS |
IT1302677B1 (en) | 1998-10-15 | 2000-09-29 | Zambon Spa | BENZAZINIC DERIVATIVES INHIBITORS OF PHOSPHODIESTERASE 4 |
IT1303272B1 (en) | 1998-10-29 | 2000-11-06 | Zambon Spa | TRICYCLIC DERIVATIVES INHIBITORS OF PHOSPHODIESTERASE 4 |
US6686502B1 (en) * | 1999-03-26 | 2004-02-03 | Ucb S.A. | Compounds and methods for treatment of asthma, allergy and inflammatory disorders |
US6740666B2 (en) | 2000-12-20 | 2004-05-25 | Merck & Co., Inc. | Substituted 8-arylquinoline phosphodiesterase-4 inhibitors |
AU2002257459B2 (en) | 2001-05-24 | 2006-12-14 | Merck Frosst Canada Ltd | 1-biaryl-1,8-napthyridin-4-one phosphodiesterase-4 inhibitors |
JO2311B1 (en) | 2001-08-29 | 2005-09-12 | ميرك فروست كندا ليمتد | Alkyne-aryl phosphodiesterase-4 inhibitors |
AR037517A1 (en) | 2001-11-05 | 2004-11-17 | Novartis Ag | DERIVATIVES OF NAFTIRIDINES, A PROCESS FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF AN INFLAMMATORY DISEASE |
IS7839A (en) | 2002-11-22 | 2004-05-23 | Merck Frosst Canada Ltd. | 4-Oxo-1- (3-substituted phenyl-1,4-dihydro-1,8-naphthyridine-3-carboxamide phosphodiesterase-4 inhibitor |
MY141255A (en) | 2003-12-11 | 2010-03-31 | Memory Pharm Corp | Phosphodiesterase 4 inhibitors, including n-substituted diarylamine analogs |
ES2624710T3 (en) * | 2011-08-23 | 2017-07-17 | Cornerstone Therapeutics Inc. | Use of zileuton in the treatment of nasal polyps in patients with cystic fibrosis |
EP3735248A4 (en) * | 2018-02-09 | 2021-11-17 | Empirico Inc. | Process to inhibit or eliminate eosinophilic diseases of the airway and related conditions |
-
2019
- 2019-12-23 AU AU2019417718A patent/AU2019417718A1/en active Pending
- 2019-12-23 JP JP2021537818A patent/JP2022515838A/en active Pending
- 2019-12-23 MX MX2021007938A patent/MX2021007938A/en unknown
- 2019-12-23 KR KR1020217023172A patent/KR20210110623A/en unknown
- 2019-12-23 WO PCT/US2019/068328 patent/WO2020139830A2/en unknown
- 2019-12-23 SG SG11202106517WA patent/SG11202106517WA/en unknown
- 2019-12-23 EP EP19843006.8A patent/EP3902567A2/en active Pending
- 2019-12-23 CN CN201980090028.XA patent/CN113423435A/en active Pending
- 2019-12-23 US US16/725,309 patent/US20200254070A1/en active Pending
- 2019-12-23 CA CA3124670A patent/CA3124670A1/en active Pending
-
2021
- 2021-06-15 IL IL284046A patent/IL284046A/en unknown
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3693352B2 (en) | Methods for detecting genetic polymorphisms and monitoring allelic expression using probe arrays | |
AU2008316313B2 (en) | A method of diagnosing neoplasms - II | |
Turner et al. | Highly individual methylation patterns of alternative glucocorticoid receptor promoters suggest individualized epigenetic regulatory mechanisms | |
US20090062131A1 (en) | Nucleic acid arrays for detecting gene expression in animal models of inflammatory diseases | |
US20080280843A1 (en) | Methods and kits for linking polymorphic sequences to expanded repeat mutations | |
Yuferov et al. | Tissue-specific DNA methylation of the human prodynorphin gene in post-mortem brain tissues and PBMCs | |
WO2008064519A1 (en) | Methods and compositions for diagnosis of esophageal cancer and prognosis and improvement of patient survival | |
US20090042824A1 (en) | Methods and Kits for Linking Polymorphic Sequences to Expanded Repeat Mutations | |
Zhu et al. | Differential expression of human COMT alleles in brain and lymphoblasts detected by RT-coupled 5′ nuclease assay | |
KR102029775B1 (en) | Biomarkers for diagnosis of Non-muscle invasive bladder cancer and uses thereof | |
JP2008545390A (en) | Methods for assessing the risk of developing lung cancer using genetic polymorphism | |
JP2006517092A (en) | Heart failure gene determination and therapeutic drug screening | |
Dokun et al. | Relationship of SNCG, S100A4, S100A9 and LCN2 gene expression and DNA methylation in bladder cancer | |
JP2001054400A (en) | Genotype determining two allele marker | |
JPWO2020154268A5 (en) | ||
JPWO2020139830A5 (en) | ||
Maxeiner et al. | Novel human sex-typing strategies based on the autism candidate gene NLGN4X and its male-specific gametologue NLGN4Y | |
Tjarnlund-Wolf et al. | Allelic imbalance of tissue-type plasminogen activator (t-PA) gene expression in human brain tissue | |
JP2003511056A (en) | Method for identifying 5-position methylated variant | |
KR101683086B1 (en) | Prediction method for swine fecundity using gene expression level and methylation profile | |
US8993242B2 (en) | Method for functional testing of site-specific DNA methylation | |
US20160312311A1 (en) | Markers for isocitrate dehydrogenase inhibitors | |
CA3133000A1 (en) | Treatment of increased lipid levels with sterol regulatory element binding transcription factor 1 (srebf1) inhibitors | |
RU2021122161A (en) | TREATMENT OF RESPIRATORY DISORDERS USING ARACHIDONATE 15-LIPOXYGENASE (ALOX15) INHIBITORS | |
RU2021121850A (en) | TREATMENT OF OPHTHALMIC PATHOLOGICAL CONDITIONS WITH ANGIOPOETIN-LIKE PROTEIN 7 (ANGPTL7) INHIBITORS |